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The occurrence of nonalcoholic fatty liver disease (NAFLD) is associated with major abnormalities of hepatic lipid metabolism. We
propose that lipid abnormalities directly or indirectly contribute to NAFLD, especially fatty acid accumulation, arachidonic acid
metabolic disturbance, and ceramide overload. The effects of lipid intake and accumulation on NAFLD and NAFLD treatment
are explained with theoretical and experimental details. Overall, these findings provide further understanding of lipid
metabolism in NAFLD and may lead to novel therapies.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the most
common liver diseases in Western countries, and its preva-
lence is increasing worldwide [1, 2]. Recently, the prevalence
of NAFLD was reported to be higher in South America and
Asia than in Europe and USA [3]. The spectrum of NAFLD
ranges from simple steatosis to nonalcoholic steatohepatitis
(NASH), fibrosis, cirrhosis, and hepatocellular carcinoma
(HCC), which is caused by excessive caloric intake without
excessive alcohol consumption [4]. Fatty liver development
without heavy drinking is generally called nonalcoholic fatty
liver (NAFL) [5]. NASH is the intensified form of NAFL,
which is associated with inflammation and different degrees
of fibrosis [5, 6]. Nearly 10%–25% of patients with NASH
may develop cirrhosis [7]. However, in some patients, NASH
can progress to hepatocellular carcinoma without significant
cirrhosis [8]. NASH is projected to be the leading cause of
liver transplantation in USA by 2020, which is due to increas-
ing disease prevalence and ineffective treatment [9].
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Recent studies on the relationship between NAFLD and
lipid disorders have demonstrated that disruption of the lipid
metabolism balance in the liver causes lipid accumulation
and consequently, hepatotoxicity, and NAFLD [10–12]. Dys-
lipidemia manifests as an increase in plasma free fatty acids
(FFA), oxidized low-density lipoprotein (ox-LDL), and tri-
glycerides (TGs), which cause inflammation, oxidative stress,
lipotoxicity, and liver damage [11, 12]. Dyslipidemia can
occur at all stages of NAFLD and aggravate the NAFLD pro-
cess. Few studies have emphasized on the role of ceramide
and arachidonic acid metabolism in the development of
NAFLD. Therefore, we reviewed the metabolic pathways
contributing to the pathogenesis of NAFLD by elaborating
the role of fatty acid (FA), ceramide, and arachidonic acid
as well as studying lipid uptake and potential treatments.
2. Factors Influencing NAFLD
Weight gain and obesity are primary risk factors for the
development of fatty liver. Further evidence suggests that diet
composition, particularly carbohydrates, has an important
role in the progression of disease to NASH and fibrosis [6].
2.1. Obesity and NAFLD.Obesity refers to the excessive accu-
mulation of body fat due to the imbalance of cellular lipo-
genic and lipolytic activities [13]. The incidence of obesity
has been increasing worldwide for the past two decades; the
prevalence in South America, Middle East, Asia, the United
States, and Europe was reported to be 31%, 32%, 27%, 24%,
and 23%, respectively [14–16]. In addition, the morbidity of
NAFLD is increasing [17]. Although the awareness emphasis
on healthy lifestyle is increasing, obesity remains a public
health problem, leading to many preventable complications
such as NAFLD [5]. A study indicated that 80% of NAFLD
patients are obese (body mass index ðBMIÞ > 30 kg/m2) as
well as the large amount of visceral adipose tissue (VAT) in
morbidly obese (BMI > 40 kg/m2) individuals which leads
to high morbidity of NAFLD [18]. Ciupińska-Kajor et al.
reported that morbid obesity is associated with a higher inci-
dence of more advanced fibrosis and confirmed that severe
fibrosis and cirrhosis are common to a greater extent in mor-
bidly obese patients with NAFLD [19]. Therefore, NAFLD
treatments are focused on weight loss through lifestyle
changes, antiobesity drugs, and bariatric surgery [20].
2.2. High-Carbohydrate Diet Intake and NAFLD. Excessive
carbohydrate intake is closely associated with the occur-
rence of NAFLD. It has been demonstrated that a high-
carbohydrate diet pattern characterized by high intake of
fruits, cakes, ice cream, soft drinks, and candied fruits is pos-
itively associated with the prevalence of NAFLD [21]. The
higher risk of NAFLD due to fruits, sugared beverages, and
snacks may be because these foods contain large amounts
of sugars such as fructose and sucrose that have been associ-
ated with the pathophysiology of NAFLD. Among the three
most important carbohydrates (glucose, fructose, and
sucrose), fructose and sucrose have some influence on the
epidemiology of NAFLD. Fructose is the main component
of sweeteners, and its intake has tripled over the past decade
[22]. It can cause liver damage through a variety of mecha-
nisms [23]. In fact, several epidemiological and experimental
studies have supported the potential pathogenic effects of
increased fructose consumption [24, 25]. Different animal
models have been studied to explore the mechanism of
fructose-induced NAFLD. In humans, excess fructose intake
is associated with elevated plasma TG level and hepatic lipid
deposition [26]. A study demonstrated that high-calorie
foods (65% sucrose foods) for 8 weeks resulted in obesity,
insulin resistance, and macrovesicular steatosis in C57BL/6
mice [27]. Hence, targeting excessive fructose and sucrose
consumption that cause NAFLD, dietary guidelines have rec-
ommended to limit added sugars (primarily sucrose and
high-fructose corn syrup (HFCS)) in the diet to a maximum
5%–10% of daily calories [28, 29].
3. Lipid Uptake in the Normal Liver
and in NAFLD
The process of lipid uptake in the liver in both physiological
and pathological conditions is mediated through liver FA
binding protein (FABP1) and CD36. Abnormal protein reg-
ulation may lead to excessive hepatic accumulation of nones-
terified FAs (NEFAs) and TG, causing cytotoxicity and
resulting in NAFLD.
3.1. CD36-Mediated Lipid Uptake. CD36 is the major recep-
tor involved in long-chain FA transport and TG storage
and is expressed in several cells such as macrophages and
monocytes [30] and tissues such as the liver, heart, and adi-
pose [31]. It recognizes modified lipoproteins such as ox-
LDL, promotes lipid-laden foam cell formation [32], and
modulates events associated with lipid utilization. Recently,
CD36 was found to play a crucial role in the liver by partici-
pating in FA uptake and storage and secretion of TG [33].
CD36 mediates FFA uptake in various tissues, and FA uptake
has a significant role in hepatic steatosis; thus, abnormalities
in CD36 may lead to hepatic steatosis [34]. The majority of
NEFAs in the blood are bound to carrier proteins (mainly
albumin), and their uptake requires dissociation from
CD36-mediated carrier proteins [35]. Excessive hepatic accu-
mulation of NEFAs and TG leads to cytotoxicity, resulting in
NAFLD progression. Li et al. indicated that CD36 is the neg-
ative regulator of lipophagy in liver cells [36]. It has been
reported that CD36 expression is significantly upregulated
in hepatic tissues of NAFLD patients [37] and overexpression
of CD36 in the liver increases TG accumulation and causes
hepatic steatosis progression [38]. The localization of CD36
on the plasma membrane of liver cells was significantly
higher in NASH patients than that in patients with normal
liver and those with simple steatosis [39]. In the livers of mice
with NASH, increased CD36 palmitoylation and CD36 local-
ization on the plasma membrane of hepatocytes were
observed. In addition, inhibition of CD36 palmitoylation
protected mice from developing NASH [39]. Briefly, CD36
expression is increased in the liver of NAFLD patients, which
leads to abnormal liver function and systemic abnormalities,
including inflammation, hepatocyte damage, hepatic lipid
accumulation, and fibrosis.
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3.2. FABP1-Mediated Lipid Uptake. FABP1 or L-FABP is
the first discovered member of the FABP family, with high
concentrations in the liver, intestine, and kidney. In addi-
tion to CD36, FABP1 mediates the uptake, transport, and
metabolism of long-chain FAs and other lipid ligands in
cells [40]. It is a soluble protein commonly found in
rodents (26% cytosolic protein; 200–400μM) and humans
(7%–10% cytosolic protein; 700–1,000μM). Recent studies
using cell and mice models have verified that FABP1 is
the key regulator of lipid metabolism and steatosis in the
liver [41]. In vitro studies revealed that FA uptake was sig-
nificantly increased with FABP1 overexpression and was
significantly decreased with FABP1 antisense ribonucleic
acid (RNA) expression [42]. A Western diet of high satu-
rated fat and high cholesterol could prevent diet-induced
obesity and hepatic steatosis in FABP1−/− mice, which
reflected changes in the kinetics of saturated FA (SFA) uti-
lization [42]. Human genetic variant of L-FABP gene is
linked to abnormal lipid metabolism [42]. Studies have
indicated that FFA-induced hepatic steatosis and liver
injury can be improved by inhibiting FABP1 expression
[41]. Downregulation of FABP1 has been identified as
the new mechanism for preventing hepatic steatosis and
liver injury [41]. Overall, similar to CD36, FABP1 overex-
pression can lead to abnormal liver functions such as dys-
lipidemia and hepatic steatosis.
4. Lipid Abnormalities in the Liver
Abnormal lipid accumulation in the liver is the pathophysio-
logical feature of NAFLD [43]. Lipid abnormalities are of
many types. This study mainly focuses on the FA-induced
hepatotoxicity, arachidonic acid metabolism and inflamma-
tion, and hepatic ceramide overload and hepatic injury.
4.1. FA Accumulation and Hepatotoxicity. Lipotoxicity is
defined as abnormal cellular lipid composition that leads to
the accumulation of toxic lipids, organelle dysfunction, cellu-
lar damage, and chronic inflammation. In this study, we
focused on the relationship between FA toxicity and NAFLD
as well as lipotoxicity, which causes direct damage to mito-
chondria and peroxisomes [44, 45]. Mitochondrial damage
results in the loss of membrane polarization, rendering mito-
chondria incapable of effectively completing β-oxidation and
energy metabolism, hence further aggravating FA accumu-
lation. FA exacerbates insulin resistance and promotes
inflammation [46–50] and fibrosis [51–53] in progressively
worsening liver cells, resulting in liver cell damage. Dam-
aged liver cells release many inflammatory mediators.
Inflammasomes, cytokines, chemokines and their receptors,
and innate and adaptive immunity cells are all induced by
liver inflammation and the direction of NASH treatment
[46–49]. Liver inflammation results in the inactivation of
tissue repair mechanisms. These mechanisms replace dam-
aged liver cells by activating the staminal compartment,
stimulating hepatocyte proliferation, and remodeling the
extracellular matrix (ECM) [54, 55]. If inflammation per-
sists for a longer period of time, ECM-forming cells are
recruited and activated, leading to excessive deposition of
ECM and eventually liver fibrosis [56]. Briefly, FA accumu-
lation causes mitochondrial damage that further aggravates
FA accumulation and results in insulin resistance and,
finally, liver inflammation and fibrosis.
4.2. Arachidonic Acid Metabolism and Inflammation. An ele-
vated level of FFA in the liver is recognized as the leading
cause of cell damage and death in NASH [57–60]. A recent
study found that although the total lipid content increased,
the liver FFA content remained unchanged in NAFLD
patients. However, the FFA level in circulation may not be
associated with that in cells. This may be because polyunsat-
urated FAs (PUFAs) play a key role, either proinflammatory
or anti-inflammatory depending on their structure, in
NAFLD progression [61]. Arachidonic acid is one of the
long-chain polyunsaturated omega-6 FAs (n-6 PUFAs),
which are the precursors of the potent proinflammatory
eicosanoids [62, 63]. The progression from simple hepatic
steatosis to NASH may be due to escalation of inflammation
[64]. Histologically, both isolated steatosis and NASH pres-
ent with intracellular lipid accumulation and lipid droplet
(LD) formation in the cytoplasm of hepatocytes; however,
no inflammation is observed in isolated steatosis, and patho-
logical inflammation resulting in cell necrosis is observed in
NASH. LDs are thought to be the source of overproduction
of proinflammatory eicosanoids, presenting early involve-
ment of arachidonic acid metabolites in NAFLD [65]. In
addition, studies with a lipidomics approach on NAFLD
patients have consistently demonstrated that a higher n-
6 : n-3 ratio in the blood and liver is associated with the pres-
ence and severity of NAFLD [61]. Another study used this
approach to quantify the major lipid species in the liver
[66] and provide some novel and interesting insights into
the pathophysiology of NAFLD. An increase in the level of
arachidonic acid and a decrease in the level of key n-3 FAs
cause the ratio of n-6 : n-3 FAs to increase. After, arachidonic
acid (20 : 4n-6) is released from membrane phospholipids by
phospholipase A2 and from the breakdown of phos-
phatidylinositol bisphosphate through diacylglycerol (DAG)
by phospholipase C; it is promptly transformed into proin-
flammatory prostaglandins, thromboxanes, and leukotrienes
by cyclooxygenase [67]. CYP4A14 is a hydroxylase that cata-
lyzes omega-hydroxylation of medium-chain FAs and ara-
chidonic acid in mice and is highly expressed in the liver.
In both NAFLD patients and mouse models, CYP4A14 was
reported to be significantly upregulated. In addition,
CYP4A14 overexpression resulted in increased hepatic lipid
accumulation in wild-type mice, whereas CYP4A14 ablation
prevented NASH progression [68]. In conclusion, arachi-
donic acid induces inflammation and, thus, plays an impor-
tant role in NAFLD.
4.3. Hepatic Ceramide Overload and Hepatic Injury. Cer-
amide, composed of an amino group of a sphingoid base,
usually sphingosine and saturated or monounsaturated fatty
acyl chains, forms the hydrophobic core of all the complex
sphingolipids (sphingomyelin, cerebral gangliosides, and
gangliosides) [57]. Ceramide is involved in key steps of the
pathogenesis of NAFLD, including the disruption of insulin
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sensitivity and mitochondrial metabolism, metabolic distur-
bance, and stimulation of cell death [69–72]. It has been
confirmed that the level of hepatic ceramide is elevated in
NAFLD and associated with the severity of liver disease
[73–75]. Hepatic ceramide overload is caused by an increase
in hydrolysis of sphingomyelin through acid sphingomyeli-
nase (ASM). Several studies have reported that elevated
levels of sphingolipid in the liver and plasma were consis-
tent with the progress of hepatic insulin resistance, hepatic
dysfunction, and steatosis in rodents [76, 77]. Generally,
serine palmitoyl transferase (SPT) stimulates the binding
of palmitoyl-CoA to serine to form sphingolipids. However,
SPT can stimulate the binding of acyl-CoAs to amino acids
to produce a group of atypical sphingoid bases such as 1-
deoxysphingolipids. Sphingolipids, especially 1-deoxysphin-
golipids, were regarded as biomarkers of NAFLD progres-
sion in a recent omics approach [78]. Myostatin, an SPT
inhibitor, reduced ceramide levels in the experimental
models of NAFLD [79, 80]. In addition, ASM is associated
with the process of simple steatosis to NASH. ASM mRNA
levels are three-fold higher in NASH patients than those in
healthy controls [81]. Moreover, ASM knockout mice are
protected from diet-induced steatosis [82] and NASH
[83]. The ASM activity is enhanced in NASH stimulated
by proinflammatory substances such as TNF-α, reactive
oxygen species (ROS), and death receptor ligands [84]
and by increased SFAs, which are the key substrates for
the de novo synthesis of ceramides. Mitochondria are the
main cellular target of ceramide, which damages FA β-oxi-
dation, promotes ROS production, TG accumulation, and
insulin resistance [85, 86]. Inhibitors such as myriocin
(SPT inhibitor) and fenretinide (inhibitor of the enzyme
catalyzing DES1 synthesis [last step of bioactive ceramide
synthesis]) have been found to ameliorate insulin resis-
tance in experimental models of NAFLD [80, 87, 88]. In
all these experiments, inhibition of ceramide synthesis
was associated with reduction of hepatic steatosis [89].
Other mechanisms of ceramide lipotoxicity in NASH are
as follows: imbalance of calcium homeostasis in the endo-
plasmic reticulum (ER), leading to ER stress-mediated
apoptosis; activation of NLRP3 inflammasome, leading to
autophagy damage; and increase in hepcidin expression,
leading to liver iron overload [83, 90–93]. In addition,
ASM activation may promote liver damage by interfering
with the metabolism of methionine and phosphatidylcholine
and, thus, contribute to permeabilization of the lysosomal
membrane [83] and activation of hepatic stellate cells
(HSCs) [81]. Moreover, ceramide has been reported to
mediate many of the adverse effects of SFAs, especially pal-
mitic acid, which is a substrate in the SPT response [71,
94]. However, weight loss was reported to reduce steatosis
and hepatocellular damage and remarkably alter the expres-
sion of ceramide-related genes in the liver. Changes in cal-
orie intake and fat consumption, particularly saturated fat,
dramatically correlated with changes in the expression of
ceramide-related genes [95]. Briefly, ceramide causes dis-
ruption of insulin sensitivity and mitochondrial metabo-
lism, imbalance of calcium homeostasis in the ER, and
ultimately liver injury.
5. Therapy
5.1. Lifestyle Changes and Medication. A strict diet control
seems to be an attractive and safe method for treating NASH.
Both the Mediterranean and ketogenic diets advocate a
reduced intake of carbohydrates. In addition, more physical
exercise routinely can prevent and relieve NAFLD by
improving lipid homeostasis. Further, statins (lipid-lowering
drugs) present some benefits for the liver.
The Mediterranean diet is characterized by decreased
intake of sugars and refined carbohydrates and enhanced
intake of monounsaturated and n-3 FAs [96]. Different types
of lipids (e.g., n-3 and n-6) may have opposite net influence
on inflammation, and therefore, the final biological net effect
is determined by their relative proportion [57]. Unlike n-6,
n-3 PUFAs have important anti-inflammatory effects; they
reduce adipogenesis and increase fatty acid oxidation
(FAO), leading to a decrease in hepatic steatosis [97–99].
Fish and n-3 PUFA intake are reported to be lower in
NAFLD patients than in nonfatty liver patients. Similarly,
a downward trend of n-3 FA, eicosapentaenoic acid
(20 : 5n-3) and docosahexaenoic (22 : 6n-3), intake is
observed in these patients considering multiple lipids [98,
99]. These two n-3 FAs have significant antiproliferative,
anti-inflammatory, and modulatory effects on the meta-
bolic and immune systems [57]. The observed decreasing
trends in the intake of these key n-3 FAs may promote
steatosis, inflammation, dyslipidemia, cell damage, and
carcinogenic risk in NASH patients [100, 101]. This
reveals the theoretical basis for NASH treatment with n-
3 FAs [73]. To date, most studies have used the methods
of complementing patients with n-3 PUFAs. In 2012, a
meta-analysis of nine studies revealed that n-3 PUFA sup-
plementation has a beneficial influence on the liver fat and
liver enzyme level [102]. The Mediterranean diet results in
reduced calories, which is acceptable by patients and
should be encouraged.
Ketogenic diets (KDs) are very low in carbohydrates and
high in fats and/or proteins compared with various diets and,
therefore, have gained popularity [103]. Low-calorie, espe-
cially low-carbohydrate, KD quickly reduces liver fat content
and related metabolic abnormalities [104]. KD has been
reported to promote weight loss, reduce intrahepatic triglyc-
eride content, and alleviate metabolic parameters in obese
patients. In addition, KD was reported to provoke weight loss
in rodents. However, maintaining a long-term KD stimulated
the progression of NAFLD and systemic glucose intolerance
in mice. Thus, the relationship between KD and systemic
insulin resistance in humans and rodents remains to be elu-
cidated [105].
Physical activity (PA) is an integral part of any therapeu-
tic strategy for weight loss, and it may play an important role
in preventing NAFLD [106–108]. Multiple cohort studies
revealed that change in body weight was correlated with both
the development and remission of NAFLD [109, 110]. In
men, initiation of an exercise regimen was remarkably asso-
ciated with NAFLD remission [111]. The role of PA in delay-
ing NAFLD progression has been demonstrated to be
beneficial in the presence and absence of one or more
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metabolic syndromes [112]. In addition, an increase in PA
prevents and/or retards NAFLD-related disease progression
independent of weight loss [113, 114]. Dietary counseling
and appropriate exercise should be combined and adjusted
according to individual circumstances, targeting a gradual
weight loss of 7%–10% [115, 116].
Atorvastatin and rosuvastatin [117] are widely used for
treating dyslipidemia; however, they have not been well
established as specific treatments for NAFLD. The guidelines
of the European Association for the Study of the Liver
(EASL)/European Association for the Study of Diabetes
(EASD)/European Association for the Study of Obesity
(EASO) [106] consider that statins have not been thoroughly
tested. However, a large number of animal and human stud-
ies have demonstrated that the use of statins was safe in
NAFLD, without an increase in the risk of hepatotoxicity,
and may even significantly reduce aminotransferases. Ani-
mal data suggested that statins had certain beneficial effects
on liver histology in NASH models [118]. Three post hoc
analyses of randomized controlled trials in humans revealed
that the use of atorvastatin had a beneficial effect on NAFLD
in terms of liver enzyme reduction and ultrasonography
improvement [118]. Statins may be the valuable option to
be considered in patients with NAFLD/NASH, as it signifi-
cantly reduces the risk of cardiovascular disease and liver
cancer simultaneously [119–148].
5.2. Targeted Therapy. NAFLD is characterized by ectopic
toxic lipid accumulation, which is due to an extensive
derangement in hepatic lipid metabolism [149–151]. Under-
lying these abnormalities is a wide range of disorder of
nuclear transcription factors that adjust lipid metabolism,
inflammation, and fibrogenesis, which consist of CD36; per-
oxisome proliferator-activated receptor- (PPAR-) α, PPAR-
δ, and PPAR-γ; farnesoid X receptor (FXR); and sterol
regulatory element binding protein 1 (SREBP-1), which are
ideal targets for NAFLD treatment [152, 153].
CD36 is a FA receptor that plays a significant role in reg-
ulating lipid and glucose use, and the upregulation of CD36
expression is associated with NASH [154]. The RNA expres-
sion of nuclear factor kappa-B (NF-κB), a key regulator
involved in the inflammation process, can be affected by the
manipulation of CD36 expression [155]. Several studies have
indicated that abnormal expression of CD36 in the liver was
markedly associated with insulin resistance, hyperinsuline-
mia, and steatosis in NAFLD patients [154]. CD36 expres-
sion was reported to be elevated in mouse models with
genetic obesity and high-fat diet- (HFD-) induced fatty livers
[37]. Hence, treatment strategies designed to reverse this pro-
cess by restoring normal levels of CD36 may provide a new
method for treating NAFLD. A study reported that the
absence of CD36 in the liver remarkably retarded the devel-
opment of hepatic steatosis, although FA level increased. In
addition, CD36 deletion affected the blood FA composition
and improved the serum markers of hepatic inflammation
[156]. Further, hepatocyte-specific loss of CD36 was found
to significantly improve whole body insulin sensitivity in
HFD-fed mice [156]. Briefly, CD36 not only is a disease
marker but also plays an active role in FA uptake and has a
significant influence on insulin sensitivity and hepatic lipid
content and composition [157].
PPAR-α, a transcription factor, is mainly expressed in
metabolically active tissues and regulates FAO. Lipid accu-
mulation owing to FAO inhibition indirectly accelerates
fibrogenesis by promoting inflammation. Agonists of
PPAR-α presented beneficial effects of reversing deficiencies
in FAO and improving NAFLD progression in animal and
cell models [157, 158]. A randomized controlled trial demon-
strated that pharmacological modulation of the PPAR-α
nuclear receptor leads to substantial histological improve-
ments in NASH patients, including the improvement of stea-
tohepatitis and alleviation of cardiometabolic risk profile,
with a sound security profile [157]. Several studies have
emphasized on developing dual agonists against PPAR-α
and PPAR-δ. The effects of PPAR-α promoted FAO [158],
and those of PPAR-δ reduced de novo lipogenesis and inhib-
ited inflammation [159, 160]. One such agent, elafibranor
(GFT505), improved diet-induced NASH in rodents [160].
Elafibranor has been reported to improve hepatic and
peripheral insulin sensitivity in humans [161]. In addition,
improvements in NASH, insulin resistance, and dyslipidemia
to some extent have been reported in long-term studies [157].
In summary, PPAR-α is important in reversing deficiencies
in FAO and alleviating NAFLD progression.
The most widely studied drugs with potential benefits for
NASH are thiazolidinediones (TZDs). TZDs such as
pioglitazone and rosiglitazone activate the nuclear receptor,
PPAR-γ, allowing preadipocyte differentiation into insulin-
sensitive, fat-storing adipocytes [106]. It is noteworthy that
the PPAR-γ ligands attenuate liver fibrosis by inhibiting
transdifferentiation of liver stellate cells into activated myofi-
broblasts, suggesting a direct hepatoprotective influence. In
addition, they present anti-inflammatory effects and increase
circulating adiponectin, which is an adipokine that resists
adipogenesis, and insulin sensitization [106]. Similarly, a
clinical research study reported that they ameliorate glycemic
control and NASH-associated parameters [162–164]. How-
ever, rosiglitazone has been withdrawn from the market in
most of the countries due to the deficiency and the possible
long-term treatment. We hold the opinion that it is necessary
to overcome this obstacle [108, 117]. According to the cur-
rent guidelines, pioglitazone is useful and is advocated for
elderly patients with advanced fibrosis, confirmed by biopsy,
who are unable to adopt or maintain lifestyle interventions
and have persistent metabolic risk factors; however, pioglita-
zone should be administered to patients with T2DM and/or
heart failure with caution [162, 165, 166]. Meta-analyses have
revealed that rosiglitazone and pioglitazone were remarkably
better than placebo in relieving balloon formation, lobular
inflammation, and steatosis [167, 168]. Pharmacological
inhibition of PPAR-γ resulted in the amelioration of NAFLD
development [169]. For instance, in HFD-fed mice, hepa-
tocyte/macrophage-specific PPAR-γ knockout protected
against hepatic steatosis and PPAR-γ knockdown induced
by RNA interfering-adenovirus vector injection improved a
fatty liver [10, 170, 171]. In summary, TZDs improved
hepatic steatosis and alleviated NASH and liver fibrosis by
increasing insulin sensitivity in skeletal muscle and adipose
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tissue, thus overcoming the direct steatogenic influence on
liver cells [171–173].
Bile acids (BAs) and their receptors (e.g., BA nuclear
receptor and FXR) play indispensable roles in regulating sys-
temic metabolism and hepatic lipid homeostasis. FXR is a
nutrient-sensing nuclear receptor in the gut and liver that
regulates glucose and fat metabolism [174]. These functions
of FXR were assessed through a quantitative proteomic anal-
ysis of mouse liver tissue [175]. Studies had found that FXR
regulates amino acid catabolism and detoxification of ammo-
nium in the livers of mice through ureagenesis and glutamine
synthesis. Further, the synthesis of ceramide pools through-
out the body was reported to be regulated by the BA/FXR
axis in the ileum and cecum [176]. Intestinal specific genetic
or pharmacological inhibition of FXR led to a decrease in
circulating ceramide levels, increase in browning of adipose
tissue, and amelioration of liver insulin resistance and liver
injury in HFD-induced obese mice [177]. Activation of
hepatic FXR has been shown to reduce liver glucose, adipo-
genesis, and steatosis in animal models [178]. FXR is impor-
tant for liver inflammation and has been proven to be a
potential therapeutic target for NASH [179, 180]. FXR acti-
vation reprograms arachidonate metabolism in mice [181]
and stimulates 1-deoxysphengolipid catabolism and thereby
attenuates the cytotoxic effects [182]. A phase 2 randomized
double-blind placebo control trial in Japan showed that
compared with placebo, high doses of obeticholic acid
(OCA) intake remarkably resolved NASH [178]. In the
FXR Ligand OCA in NASH Treatment (FLINT) trial, OCA
induced NASH remission in 22% of patients, whereas pla-
cebo induced NASH remission in 13% of patients [157]. In
summary, FXR regulates circulating ceramide levels and
improves hepatic insulin resistance and liver damage in
NAFLD/NASH patients.
Hepatic de novo lipogenesis is stimulated by activation
of the nutrient-sensing mTorc1 pathway, a substrate of
insulin-Akt signaling under physiological conditions [179].
For example, treatment of hepatocytes with rapamycin, an
allosteric inhibitor of mTorc1, inhibited insulin activation
of the lipogenic transcription factor SREBP-1c [183, 184].
In addition, specific knockout of the mTorc1-defining com-
ponent, raptor, in the liver alleviated HFD-induced hepatic
steatosis, which may be due to reduced lipogenesis [185]. It
has been demonstrated that Notch antagonism uncouples
Akt from mTor activation, implying that NAFLD can be
treated by Notch antagonists [186].
6. Conclusion
This article documented recent advances in lipid abnormali-
ties in NAFLD. We proposed that an abnormality in lipid
metabolic pathways eventually leads to NAFLD. This view-
point was theoretically and experimentally validated by elab-
orately elucidating the role of FA, arachidonic acid metabolic
disorders, and ceramide overload in the pathogenesis of
NAFLD. In addition, we offered some treatment options for
NAFLD. All these observations and experimental findings
provide the scientific basis for the prevention and treatment
of NAFLD.
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